CellCept
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | CellCept |
|---|---|
| Active Substance | mofetilmikofenolat |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept (tvrda kapsula, prašak za koncentrat za otopinu za infuziju, prašak za oralnu suspenziju, tableta) |
| Distribution | Supply through pharmacies (community) |
| ATC Code | L04AA06 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
| Educational materials for healthcare professionals |
Upitnik za zdravstvene radnike, verzija 1 Obrazac za prijavu i praćenje trudnoće za zdravstvene radnike, verzija 1 Vodič za zdravstvene radnike, verzija 2 |
| Educational materials for patients / caregivers |
Vodič za bolesnike, verzija 2 Upitnik za bolesnike, verzija 1 |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o izmijenjenim preporukama za kontracepciju povezanim s primjenom mofetilmikofenolata/mikofenolatne kiseline (CellCept, Myfortic, Trixin) | 22.01.2018 | Roche d.o.o., Novartis Hrvatska d.o.o., Pliva Hrvatska d.o.o. |
